ARTICLE

Received 14 Mar 2014 | Accepted 9 Oct 2014 | Published 24 Nov 2014

DOI: 10.1038/ncomms6535

Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome

Corey L. Anderson^{1,†}, Catherine E. Kuzmicki², Ryan R. Childs², Caleb J. Hintz², Brian P. Delisle³
& Craig T. January²

It has been suggested that deficient protein trafficking to the cell membrane is the dominant mechanism associated with type 2 Long QT syndrome (LQT2) caused by Kv11.1 potassium channel missense mutations, and that for many mutations the trafficking defect can be corrected pharmacologically. However, this inference was based on expression of a small number of Kv11.1 mutations. We performed a comprehensive analysis of 167 LQT2-linked missense mutations in four Kv11.1 structural domains and found that deficient protein trafficking is the dominant mechanism for all domains except for the distal carboxy-terminus. Also, most pore mutations—in contrast to intracellular domain mutations—were found to have severe dominant-negative effects when co-expressed with wild-type subunits. Finally, pharmacological correction of the trafficking defect in homomeric mutant channels was possible for mutations within all structural domains. However, pharmacological correction is dramatically improved for pore mutants when co-expressed with wild-type subunits to form heteromeric channels.

¹Department of Biophysics, University of Wisconsin, Madison, Wisconsin 53705, USA. ²Department of Medicine, University of Wisconsin, Madison, Wisconsin 53792, USA. ³Department of Physiology, University of Kentucky, Lexington, Kentucky 40536, USA. † Present address: The Wisconsin Institutes for Discovery, Madison, Wisconsin 53715, USA. Correspondence and requests for materials should be addressed to C.L.A. (email: clander2@wisc.edu) or to C.T.J. (email: ctj@medicine.wisc.edu).

Kv11.1 is a voltage-gated K^+ channel encoded by the human *ether-a-go-go-related gene* (*hERG* or *KCNH2*) and is associated with the pathophysiology of inherited cardiac arrhythmia diseases, including type 2 long QT syndrome (LQT2)¹, sudden infant death syndrome (SIDS)² and short QT syndrome³, as well as various forms of cancer⁴, epilepsy⁵ and schizophrenia⁶. Nearly 500 *KCNH2* mutations have been linked to LQT2—which is characterized by a prolonged time duration from ventricular depolarization to repolarization (QT interval on an ECG)—and increased risk for sudden cardiac death. These loss-of-function mutations have been classified into four molecular mechanisms: class 1, abnormal transcription/translation; class 2, deficient protein trafficking; class 3, abnormal channel gating/kinetics; and class 4, altered channel permeability, in all of which the repolarizing outward K^+ current, $I_{Kv11.1}$ or I_{Kr} , is reduced⁷. While a fraction of *KCNH2* mutations are nonsense and are postulated to invoke a class 1 mechanism due to nonsense-mediated mRNA decay⁸, the majority are missense mutations, with most postulated to invoke a class 2 mechanism due to protein misfolding and endoplasmic reticulum-associated degradation (ERAD)^{9–12}.

Interestingly, for some trafficking-deficient mutations, the defect can be corrected pharmacologically (usually with high-affinity Kv11.1 channel blockers), with reduced culture temperature, or by RNA interference^{10,13–16}, suggesting therapeutic potential for LQT2 carriers, although application of these findings to LQT2 patients remains a major challenge. In addition, of the >300 missense mutations, most remain functionally uncharacterized and are spread throughout the Kv11.1 multidomain protein, which contains voltage sensor (VSD, S1–4) and pore (S5–6) domains comprising the transmembrane domain (TMD)¹⁷, an amino-terminus containing the PerArntSim domain (PASD) with PAS-cap collectively making up a conserved ‘EAG’ domain present in the EAG family of Kv channels¹⁸, and a carboxy-terminus containing the cyclic-nucleotide-binding homology domain (CNBHD)¹⁹ along with a distal C-terminal ER retention signal (RXR)²⁰ and coiled-coil domain (CCD)²¹. Furthermore, carriers of LQT2 mutations are heterozygous, making co-assembly dynamics (dominant negative, haploinsufficiency) of the tetrameric channel another factor contributing to disease complexity²². While much has been learned about the molecular basis underlying LQT2 (ref. 23), many important gaps remain, three of which we address in this paper.

1. Not all mutations characterized in heterologous expression systems show a loss-of-function phenotype, suggesting that some reported mutations may be benign sequence variants or single-nucleotide polymorphisms (SNPs)^{10,24}. This emphasizes the need to functionally express and analyse individual mutations.
2. The location of a mutation within the Kv11.1 protein may be important, but the molecular basis for this is unknown. Mutations in the pore clinically have a more severe phenotype^{25,26}. Several lines of evidence suggest that TMD (including pore) and CNBHD mutations invoke a class 2 (trafficking-deficient) mechanism^{10,27} versus intracellular (‘core’) mutations that may traffic normally and exert a class 3 (abnormal gating) mechanism²⁸. ‘Core’ interactions between the PASD, S4–S5 linker and CNBHD regulate Kv11.1 gating^{29–35}, and many engineered and LQT2-linked ‘core’ mutations exhibit more rapid deactivation^{18,32,36}. A recent study reported that some PASD mutations traffic normally²⁸. Alternatively, differences may be attributed to differences in wild type (WT)–mutant subunit interactions. Several intracellular mutations reduce $I_{Kv11.1}$

in a partially dominant-negative manner or through haploinsufficiency^{10,37–39}, while most pore mutations have a strong dominant-negative interaction with WT subunits producing little to no current^{10,14,40,41}. Unfortunately, most LQT2 mutations remain functionally uncharacterized and the disease mechanisms are unknown.

3. Studies using mostly homomeric channels show that culture in the presence of pore-blocking drugs such as E4031, which involve π -cation, π - π stacking and hydrophobic interactions with aromatic residues in TMD S6 (refs 42,43), can correct defective protein trafficking of some mutations in the TMD (pore and VSD) and PASD^{10,38,44}. Second-site S6 mutations can also correct some pore mutations⁴⁵. These findings and the observation that E4031-corrected channels are more resistant to proteases suggest that E4031 correction works by stabilizing the pore, which can also facilitate cooperative folding between domains/subunits, resulting in more tightly packed channels that evade ERAD⁴⁶. However, E4031 correction seems limited primarily to pore domain mutations, along with a few in the PASD and none in the CNBHD^{10,28}. E4031-dependent pharmacological correction has been studied for relatively few homomeric and even fewer heteromeric (with WT) expressed mutations; thus, a comprehensive analysis of mutations co-expressed with WT subunits across multiple structural domains is needed to better understand pharmacological correction as a potential therapy.

In the present work, we undertook a large-scale analysis of LQT2 missense mutations in different structural domains of the Kv11.1 protein to generate new insights about LQT2 disease mechanisms. We studied missense mutations because they are the most commonly identified genetic abnormality in patients with LQT2. We adopted a data-driven approach employing heterologous mammalian expression to generate immunoblot and electrophysiology data, combined with computational structural models, to characterize both homotetrameric (mutant or WT) and heterotetrameric (mutant + WT) channels. We generated and studied 167 LQT2 mutations as well as three *KCNH2* SIDS mutations and two SNPs. We showed that 88% of LQT2 missense mutations in the PASD, C-linker/CNBHD and pore domains invoke a class 2 (trafficking-deficient) mechanism, but with some major differences. Over 70% of LQT2 pore mutations were strictly dominant negative, whereas PASD or C-linker/CNBHD mutations were not. In addition, LQT2 mutations in all domains were pharmacologically (E4031) correctable (PASD > pore > C-linker/CNBHD), and this improved dramatically when mutations were co-expressed with WT subunits (pore > PASD > C-linker/CNBHD), making pharmacological correction much more common than previously thought. We also mapped each mutation to structural models to analyse structure/(dys)function relationships. We then combined these results with previously published studies (see supplementary tables) and discuss here a simplified model for the different Kv11.1 trafficking phenotypes. To our knowledge, this is the largest mutational study for any congenital disease, which should serve as a valuable resource and help spark further inquiry into this ion channelopathy.

Results

Trafficking phenotype of homomeric EAGD mutations. We compiled a list of 291 LQT2 and 10 SIDS-linked *KCNH2* mutations, as well as 28 SNPs (see Methods, Fig. 1 and Supplementary Table 1). While the TMD contains 1/2 of the LQT2 missense mutations, the PASD is another ‘hotspot’ with at least 62 (61 LQT2, 1 SIDS) mostly uncharacterized mutations at 47 sites. Two more are located in the N-terminal proximal to the PASD in

Figure 1 | Topology of Kv11.1. (a) Cartoon of Kv11.1 with circles representing amino acids and cylinders representing TMD segments 1–6 and the S4–S5 linker. S1–S4 make up the VSD and the pore is located between S5 and S6. The intracellular PASD, CNBHD and CCD are labelled in light blue. Black and blue circles show the location of all reported LQT2 and SIDS mutations, respectively. Red circles show the location of all reported SNPs. The ER retention signal RXR is highlighted in yellow and the glycosylation site at N598 is shown with a blue diamond. (b) Linear representation of the different Kv11.1 domains (to scale) showing the number and domain location of all LQT2-linked and SIDS mutations identified to date. The numbers characterized in this study are in parentheses (59 of 64 mutations for the EAGD, 73 of 100 mutations for the pore, 29 of 41 mutations for the C-linker and CNBHD, and 9 of 36 mutations for the distal C-terminus).

the PAS-cap amphipathic helix (amino acids 13–23) (Fig. 2c)⁴⁷. To determine their trafficking phenotype, immunoblot was performed on transiently transfected HEK293 cells expressing homomeric Kv11.1 channels cultured at physiological temperature (37 °C) as well as reduced culture temperature (27 °C for 24 h), or with 10 μ M E4031 in the culture medium (24 h) to test for correction. Kv11.1 protein (132 kDa) is synthesized in the ER, where it undergoes N-linked core-glycosylation (135 kDa) and then traffics to the golgi for N-linked complex glycosylation (155 kDa) before reaching the plasma membrane. A doublet on immunoblot (135- and 155-kDa bands) indicates cell surface trafficking, whereas a lack or decrease of the 155-kDa band indicates deficient trafficking^{9,10}. Figure 2a shows representative immunoblots ($n \geq 2$) for 57 PASD mutations, which exhibited four different trafficking phenotypes: trafficking deficient and uncorrectable (red), trafficking deficient but correctable with culture at 27 °C (yellow), trafficking deficient but correctable with culture at 27 °C or with E4031 (light blue), or normal trafficking (blue). Of the 57 mutations, 49 (86%) lacked or had a diminished 155-kDa band on immunoblot compared to WT under control conditions. Among these 40 (82%) were temperature correctable and 23 (47%) were E4031 correctable. Interestingly, 17 were only temperature correctable but none were only E4031 correctable. So, in contrast to a previous study²⁸, most PASD mutations are trafficking deficient and correctable. These data, combined with several mutations already reported in the literature, are summarized in Supplementary Table 2.

Quickened deactivation from N-terminus truncated channels and LQT2 mutations can be restored by adding back the EAG domain or just the first 16 residues of the PAS cap^{18,31,48}. Binding of the PASD to the CNBHD is thought to position the

amphipathic helix and in turn the N-terminal residues near the bottom of S6 to modulate Kv11.1 gating^{30,34,35}. We further tested to see if the PAS cap is also important for trafficking, and found that deletion of residues 2–9 had no effect on trafficking, but that deletion of residues 2–24 containing the amphipathic helix did impair trafficking. The LQT2 mutations D16A and R20G were both trafficking-competent (Fig. 2b).

Structural and functional properties of EAGD mutations.

EAGD mutations were mapped onto its structure (PDB: 4HP9)⁴⁹, which has a fold consisting of a central antiparallel β -sheet flanked by several α -helices (Fig. 2c). While the different trafficking-deficient phenotypes are scattered, showing no correlation with location, most trafficking-competent mutations lie near its hydrophobic surface, which interfaces with the CNBHD (PDB: 4LLO)³⁵, a region important for regulating Kv11.1 deactivation^{18,50,51} (Fig. 2d; Supplementary Fig. 1a,b,g,h). To determine their electrophysiological properties, stably transfected cells were generated for the trafficking-competent D16A, R20G, E58D, V115M, F125C, E130K mutations, as well as the trafficking-deficient M124R located near the hydrophobic surface. Representative western blots and peak tail $I_{Kv11.1}$ densities are shown in Supplementary Fig. 2a. The greatest change in $V_{1/2}$ was for D16A and E130K, which were shifted +13 and –10 mV, respectively (Fig. 3a,b). Deactivation measured at –50 mV was slower for D16A and faster for M124R compared to WT, consistent with previous reports (Fig. 3c)^{47,52}, and D16A, R20G and E58D all exhibited slightly slower inactivation at 0 mV (Fig. 3d). In contrast, the functional properties of E58D, V115M and F125C were similar to WT, suggesting that they may be

Figure 2 | Trafficking phenotype and structural context of LQT2-linked EAGD missense mutations. (a,b) Representative immunoblots of transiently transfected HEK293 cells comparing trafficking under control culture conditions at 37 °C, at reduced temperature (27 °C, 24 h) or in E4031 (E4, 24 h). Dashes (–) indicate the 140-kDa molecular weight marker. Mutations are colour-coded as follows: trafficking deficient and uncorrectable in red, trafficking deficient but correctable at 27 °C in yellow, trafficking deficient but correctable at 27 °C or with E4031 in light blue, and those that traffic similar to WT in blue. (c) Crystal structure of the EAGD (PDB: 4HP9). Mapped LQT2 residues correspond to panel a and uncharacterized mutations (I96V and D102A) are in black. (d) Representation of the EAGD (PDB: 4HP9) complexed with the C-linker/CNBHD model from alignments to the structure of the EAGD-CNBHD complex from mouse (PDB: 4LLO). C-linker region is shown in green, CNBHD in blue and intrinsic ligand in magenta. Mutations that are trafficking competent (blue balls) are labelled. An example of a full-length immunoblot can be found in Supplementary Fig. 2.

benign variants (Table 1; Fig. 3a–d). In addition to M124R, stable cell lines of F106L also exhibited the same trafficking phenotype as transient transfections, showing a weak 155-kDa band on immunoblot, which increased with culture at reduced temperature or with E4031 (Supplementary Fig. 2d).

Trafficking of homomeric CNBHD mutations. The C-terminus of Kv11.1 contains a CNBHD coupled to the pore through a C-linker region (C-linker/CNBHD, PDB: 3UKN)¹⁹. This domain contains at least 41 (39 LQT2, 2 SIDS) mostly uncharacterized mutations at 33 sites. To determine their trafficking phenotype we used the same immunoblot assay and colour-code presentation as described for EAGD. Figure 4a shows representative immunoblots ($n \geq 2$) for 29 mutations. In all 24(82%) lacked or had a diminished 155-kDa band on immunoblot compared to WT for control (37°C) culture conditions. Of these, 15 (62%) were correctable with culture at 27°C and 5 (17%) were correctable with culture in E4031. Similar to the EAGD, 10

mutations were only temperature correctable but no mutations were only E4031 correctable. These data, combined with several mutations already reported in the literature, are summarized in Supplementary Table 3. Since this is the first report of an E4031 correctable C-terminal mutation, we tested to see if it acts through the same pore drug-binding site^{42,43}. Indeed, F656C, which traffics normally but attenuates E4031 drug block of $I_{Kv1.1}$, abolished E4031 correction of R752Q (Fig. 4b).

Structural and functional properties of CNBHD mutations. Mutations were mapped onto a homology model of the C-linker/CNBHD (residues 666–749) described in the methods (Fig. 4c; Supplementary Fig. 1c,d). Each monomer consists of a β -roll motif containing a short β -strand, with F860 and L862 forming an ‘intrinsic ligand’ rather than a modulatory ligand (PDB: 3UKN)^{19,35,53}. While the different trafficking-deficient phenotypes are scattered, showing no correlation with location, most of the uncorrectable mutations (red) lie inside the β -roll and

Figure 3 | Electrophysiological properties of LQT2-linked EAGD and C-linker/CNBHD missense mutations. (a,e) Activation current-voltage (I - V) relationships. From a holding potential of -80 mV, cells were depolarized to voltages between -70 and 50 mV in 10 -mV increments for 3 s to quantify the tail current. I - V relations were determined by normalizing peak tail currents (I_{tail}) from each step to the maximal peak I_{tail} . (b,f) $V_{1/2}$ and slope factors. The voltage at which peak $I_{Kv11.1}$ was half-maximal ($V_{1/2}$) and the slope factor (k) were determined by fitting the normalized I - V relationship with the Boltzmann function. (c,g) WT-to-mutant time constant ratios (speeding factor) for deactivation at -50 mV. The fast (τ_{fast}) and slow (τ_{slow}) time constants of channel deactivation were determined with a double exponential fit of the I_{tail} decay from 50 to -50 mV (red trace). (d,h) Inactivation time constants determined at 0 mV. From a holding potential of -80 mV, cells were depolarized to 50 mV for 1.5 s to open and inactivate channels, followed by a short 10 -ms step to -100 mV to remove inactivation without allowing enough time for the channels to deactivate. This was followed by test pulses from -30 to 60 mV in 10 -mV increments. Inactivation time constants for each step were fit with a single exponential. Error bars are s.e.m. Asterisks indicate statistical significance ($P < 0.05$). $n = 3$ to 9 HEK293 cells for each experiment.

near the intrinsic ligand, suggesting that disruption of this subdomain is highly destabilizing. (Fig. 4c,d). Previous studies have shown that a hydrophobic patch that interfaces with the EAGD, and an acidic patch are important for regulating Kv11.1 deactivation^{30,36} (Fig. 4d; Supplementary Fig. 1e-h). Surprisingly, of the trafficking-competent mutations, only R791W lies close to a gating microdomain at the interface with the EAGD.

S706C, I711V and R835W are largely buried but near the C-linker/CNBHD dimer interface, while D767Y is not located near any known gating microdomain (Supplementary Fig. 1c,g,h). To determine their electrophysiological properties, stable cell lines were generated for each of these with representative immunoblots and $I_{Kv11.1}$ densities as shown in Supplementary Fig. 2A. The functional properties of S706C were similar to those

Table 1 | Electrophysiological properties of Kv11.1 missense mutations.

LQT2	Current density (pA pF ⁻¹)	Activation		Deactivation at -50 mV		Inactivation at 0 mV
		V _{1/2} (mV)	Slope (mV/e-fold)	τ _{slow} (s)	τ _{fast} (ms)	τ (ms)
WT	97.7 ± 6.2 (9)	-8.3 ± 0.4 (5)	6.5 ± 0.4 (5)	5.3 ± 0.3 (5)	835 ± 32 (5)	12.4 ± 0.7 (3)
D16A	57.3 ± 12.4 (4)	4.9 ± 2.5* (4)	6.9 ± 0.4 (4)	9.3 ± 0.8* (4)	1281 ± 105* (4)	17.7 ± 0.1* (4)
R20G	48.5 ± 7.7 (4)	-15.0 ± 1.2 (4)	6.6 ± 0.2 (4)	6.1 ± 0.1 (4)	943 ± 119 (4)	17.8 ± 1.8* (4)
E58D	62.2 ± 9.7 (8)	-8.8 ± 1.5 (7)	7.5 ± 0.3 (7)	4.9 ± 0.3 (8)	746 ± 37 (8)	16.1 ± 0.6* (4)
V115M	73.1 ± 15.3 (9)	-9.2 ± 0.7 (8)	6.8 ± 0.2 (8)	5.1 ± 0.5 (4)	863 ± 48 (4)	12.7 ± 0.1 (3)
M124R	21.6 ± 5.3 (7)	-7.3 ± 1.6 (4)	7.6 ± 0.3 (4)	2.2 ± 0.1* (5)	430 ± 28* (5)	n/a
F125C	54.1 ± 13.7 (9)	-11.2 ± 1.4 (9)	6.7 ± 0.1 (9)	3.4 ± 0.2 (9)	615 ± 33 (9)	13.0 ± 0.5 (4)
E130K	43.2 ± 6.1 (7)	-19.4 ± 1.9* (9)	6.6 ± 0.3 (9)	6.9 ± 0.7 (7)	922 ± 65 (7)	10.4 ± 0.3 (6)
S706C	97.7 ± 6.2 (6)	-14.4 ± 2.3 (5)	6.6 ± 0.4 (5)	5.6 ± 0.7 (5)	914 ± 65 (5)	13.4 ± 1.6 (3)
I711V	45.5 ± 4.0 (4)	-5.9 ± 1.8 (4)	7.6 ± 0.6 (4)	3.2 ± 0.2* (4)	512 ± 16* (4)	n/a
D767Y	73.1 ± 9.7 (5)	-21.0 ± 1.2* (5)	6.1 ± 0.2 (5)	3.8 ± 0.3 (4)	741 ± 82 (4)	11.4 ± 0.4 (4)
R791W	105 ± 11 (4)	-20.5 ± 1.4* (4)	6.1 ± 0.2 (4)	3.1 ± 0.6* (4)	620 ± 104 (4)	16.0 ± 2.6 (4)
R835W	17.2 ± 1.8 (5)	7.8 ± 1.6* (5)	9.0 ± 0.6* (5)	1.9 ± 0.2* (4)	416 ± 31* (4)	12.6 ± 0.2 (3)
R1005Q	97.7 ± 6.2 (7)	-14.6 ± 0.5* (7)	6.4 ± 0.3 (7)	4.7 ± 0.3 (6)	823 ± 43 (6)	15.1 ± 0.6 (5)
L1049P	34.6 ± 4.5 (7)	-17.0 ± 2.5* (5)	7.7 ± 0.6 (5)	11.3 ± 1.0* (5)	1440 ± 24* (5)	10.6 ± 0.5 (5)
L1066V	74.3 ± 8.7 (6)	-0.5 ± 0.8* (5)	7.1 ± 0.4 (5)	4.0 ± 0.2 (4)	719 ± 29 (4)	18.9 ± 1.1* (4)
V644L	62.0 ± 6.4 (12)	-10.6 ± 1.7 (7)	6.6 ± 0.4 (7)	4.8 ± 0.3 (4)	790 ± 87 (4)	8.9 ± 0.3* (5)
I662T	73.1 ± 10.0 (8)	-8.4 ± 1.0 (6)	7.3 ± 0.1 (6)	7.5 ± 0.6 (5)	822 ± 57 (5)	10.6 ± 0.6 (4)

Values with an asterisk indicate statistical significance (P<0.05) compared with WT assessed using one-way analysis of variance followed by the Tukey post hoc test.

Figure 4 | Trafficking phenotype and structural context of LQT2-linked C-linker/CNBHD LQT2 missense mutations. (a,b) Representative immunoblots of transiently transfected HEK293 cells comparing trafficking under control conditions at 37 °C, at reduced temperature (27 °C, 24 h) or in E4031 (E4, 24 h). Dashes (–) indicate the 140-kDa molecular weight marker. Mutations are colour-coded as follows: trafficking deficient and uncorrectable in red, trafficking deficient but correctable at 27 °C in yellow, trafficking deficient but correctable at 27 °C or with E4031 in light blue, and those that traffic similar to WT in blue. (c) Model of the C-linker/CNBHD with C-linker region in green, CNBHD in blue and intrinsic ligand in magenta. Mapped LQT2 residues correspond to panel a and uncharacterized mutations (L678P, L693P, I728F) are in black. (d) Representation of the EAGD (coloured wheat) (PDB: 4HP9) complexed with the C-linker/CNBHD model from alignments to the structure of the EAGD-CNBHD complex from mouse (PDB: 4LLO).

of WT, in contrast to a previous report showing small changes in gating (Table 1; Fig. 3e–h)³⁶. The $V_{1/2}$ of D767Y and R791W were both shifted by -12 mV, while that for R835W was shifted by $+16$ mV (Fig. 3e,f), and deactivation measured at -50 mV for I711V, R791W and R835W was faster compared to WT (Fig. 3g). To our knowledge, these are the first reports of class 3 (altered gating) LQT2-linked CNBHD mutations studied in a mammalian expression system.

Trafficking of homomeric pore mutations. At least 100 pore missense mutations have been linked to LQT2, yet the majority remain uncharacterized. To determine their trafficking phenotype, we used the same immunoblot assay and colour-code presentation described for the EAGD with the exception of orange indicating E4031 correctable only. Figure 5a shows representative immunoblots ($n \geq 2$) for 71 mutations. In all 60 (85%) lacked a 155-kDa band on immunoblot compared to WT under control

culture conditions. Of these, 12 (20%) were correctable with culture at 27°C and 20 (33%) were correctable with culture in E4031. Interestingly, eight were only E4031 correctable and none were only temperature correctable, in contrast to the PASD and CNBHD. These data, combined with several mutations already reported in the literature, are summarized in Supplementary Table 4.

Structural and functional properties of pore mutations.

Mutations were mapped onto a previously published model of the open state (Fig. 5b)⁵⁴. A few patterns emerge. First, most of the trafficking-competent mutations are located in S6. Second, most S5 mutations have a severe trafficking phenotype, with all 14 being trafficking deficient and only 2 correctable. Finally, most trafficking-deficient but correctable mutations lie in the pore linker between S5 and S6 (Fig. 5b,c). Similar to the PASD and C-linker/CNBHD, some residues contain more than one

Figure 5 | Trafficking phenotype of LQT2-linked pore missense mutations. (a) Representative immunoblots of transiently transfected HEK293 cells comparing trafficking under control conditions at 37°C , at reduced temperature (27°C) or in E4031 (E4). Dashes (–) indicate the 140-kDa molecular weight marker. Mutations are colour-coded as follows: trafficking deficient and uncorrectable in red, trafficking deficient but correctable at 27°C or with E4031 in light blue, trafficking deficient but only correctable with E4031 in orange, and those that traffic similar to WT in blue. (b) Structural model of the pore with Terfenadine (blue molecule) modelled into the putative drug-binding domain⁵⁴. Mapped LQT2 residues correspond to panel a and uncharacterized mutations (M574R and L622F) are in black. (c) Linear representation of the S5–S6 pore linker with helices represented as cylinders and coloured dots representing the different trafficking phenotypes associated with each residue (for example, G626).

LQT2-linked mutation with different trafficking phenotypes (Fig. 5c). For example, G626A in the selectivity filter traffics normally, whereas G626D and G626V are trafficking deficient and uncorrectable and G626S is only E4031 correctable (Fig. 5a,b).

To determine if the trafficking-competent pore mutations express currents, stably transfected cell lines were generated for V644L, S649L, G657R (a conserved glycine) and I662T, all located in S6, as well as Y616C located in the pore helix. All showed a 155-kDa band, but only V644L, G657R and I662T expressed large-amplitude $I_{Kv11.1}$ (Supplementary Fig. 2a). By contrast, stable cell lines for Y616C (6.0 ± 1.0 pA pF⁻¹, $n = 8$) and S649L (2.5 ± 0.6 pA pF⁻¹, $n = 8$) showed minimal $I_{Kv11.1}$, suggesting a class 4 (altered permeation) mechanism. For the G657R mutation, depolarizing voltage steps to -70 to 50 mV also resulted in activation of no outward $I_{Kv11.1}$, whereas a low-amplitude inward tail current was elicited by a voltage step to -120 mV, suggesting a class 3 mechanism (Supplementary Fig. 2b,c). The functional properties of I662T were similar to WT, but V644L exhibited faster inactivation measured at 0 mV

consistent with a class 3 (abnormal gating) mechanism (Table 1; Fig. 6c–f).

Several LQT2-linked mutations introduce a polar residue or proline and may decrease membrane insertion efficiency, a mechanism underlying other membrane protein-misfolding diseases^{55–57}. Using the ΔG predictor tool⁵⁸, we found that 10 of 17 S5 mutations, but only 1 in S6, are predicted to insert less efficiently ($\Delta\Delta G \geq 0.5$), which might partially explain why most S5 mutations have a severe trafficking phenotype that is not correctable and most in S6 mutations traffic normally. Mutations in S1–S4 were also modeled using the ΔG predictor tool and only 2 of 20 mutations (both in S1) had a $\Delta\Delta G \geq 0.5$. Interestingly, several mutations in S2 and S3 and all in S4 occur at charged residues important for voltage sensing, but these also may be important for membrane insertion (Supplementary Table 5)⁵⁹.

Structural and functional properties of C-terminal mutations.

The distal C-terminus (residues beyond the CNBHD) contains at least 36 (31 LQT2, 5 SIDS) mostly uncharacterized mutations and 16 SNPs, several of which are located in or near the CCD and ER retention signal (RXR) (Figs 1a and 6a). Immunoblot analysis ($n \geq 2$) of transiently transfected HEK293 cells revealed that all eight LQT2 mutations, one SIDS and two SNPs tested traffic similar to WT (Fig. 6b).

To determine their electrophysiological properties, stably transfected HEK293 cells were generated for R1005Q in the RXR as well as L1049P and L1066V, which are at the hydrophobic interface of the CCD (Supplementary Fig. 2a). The $V_{1/2}$ of R1005Q and L1049P shifted -6 and -9 mV, respectively, and L1066V shifted $+8$ mV. L1049P also exhibited slower deactivation at -50 mV and L1066V exhibited slower inactivation at 0 mV (Table 1; Fig. 7c–f). Interestingly, Paircoil2 analysis predicted that L1049P, but not L1066V, disrupts the CCD, which might explain their slightly different functional characteristics even though they are similarly located.

Trafficking of LQT2 mutations co-expressed with WT.

Since LQT2 is an autosomal dominant disease where only one abnormal allele is present, immunoblots were also performed on HEK293 cells co-transfected with equal amounts of WT and mutant DNA. Immunoblot analysis ($n \geq 2$) showed that nearly all missense mutants exhibited a diminished 155-kDa band compared to WT alone (Fig. 7a–c). A few mutations such as H70R and A78P in the PASD, H687Y and S735L in the CNBD, and S660L in the pore showed a 155-kDa band similar to WT. However, in contrast to the PASD and CNBHD, where nearly every mutation showed at least a weak 155-kDa band, 44 of 58 (76%) pore mutations completely lacked a 155-kDa band (Fig. 8c, indicated as *). Thus, in the pore domain the presence of mutant α -subunit(s) is strictly dominant-negative for the majority of mutations.

To determine if co-expression of mutant + WT alleles changes the trafficking phenotype of HEK293 cells cultured in E4031, immunoblot analysis ($n \geq 2$) was performed on 10 PASD mutations and no differences were found from homomeric channels. Eight mutations remained uncorrectable with culture in E4031, while two positive controls (F106Y and E58K) were still correctable (Fig. 8a). Similarly, co-expression of WT + 10 C-linker/CNBHD mutations was tested and no differences in E4031 response were found (Fig. 8b). However, when 42 pore mutations were co-expressed with WT, including four previously reported (A561P, A561T, Y611H and A614V)¹⁰, 35 (83%) showed enhancement of the 155-kDa band (Fig. 8c). Of these 35, 20 demonstrated improvement of the 155-kDa band with

Figure 6 | Trafficking phenotype of LQT2-linked distal C-terminal missense mutations. (a) Helical wheel diagram showing two of the four helices forming the coiled-coil domain with LQT2 mutations underlined in black, SIDS mutations in blue and SNPs in red. (b) Representative immunoblots of transiently transfected HEK293 cells comparing trafficking under control conditions at 37°C and at reduced temperature (27°C). Dashes (—) indicate the 140-kDa molecular weight marker. (c) I - V relationships. (d) $V_{1/2}$ and slope factors. (e) WT-to-mutant time constant ratios (speeding factor) for deactivation at -50 mV. (f) Inactivation time constants determined at 0 mV. Protocols are described in Fig. 3. Error bars are s.e.m. Asterisks indicate statistical significance ($P < 0.05$). $n = 4$ to 12 HEK293 cells for each experiment.

Figure 7 | Trafficking phenotype of LQT2 missense mutations co-expressed with WT. Representative immunoblots of transiently transfected HEK293 cells co-expressing WT with (a) PASD mutants, (b) C-linker/CNBHD mutants, or (c) pore mutants as heteromeric channels under control conditions. Dashes (–) indicate the 140-kDa molecular weight marker. Asterisks (*) indicate complete absence of the 155-kDa band.

culture at reduced temperature or with E4031 that was not correctable with reduced temperature or with E4031 as homomeric channel (blue asterisks). Seven showed improved trafficking with E4031 that was not correctable with E4031 as homomeric channel (orange asterisks), and 8 could be corrected with reduced temperature that was not temperature correctable as homomeric channels (yellow asterisks). Thus, in the pore domain, correction of trafficking-deficient mutations depends on α -subunit composition and is enhanced by the addition of WT α -subunits.

Discussion

Our data-driven approach provides new insights into LQT2 that would not have otherwise been possible. First we identified a loss-of-function mechanism for most of the LQT2-linked missense mutations in three structural domains. Including previously published findings with our present findings (Fig. 9b and Supplementary Tables 1–4), 193 PASD, C-linker/CNBHD and pore mutations have been studied and 169 (88%) demonstrate a class 2 (trafficking-deficient) mechanism. This is in contrast to a smaller study of 10 PASD mutations that suggested most traffic

Figure 8 | Correction of heteromeric Kv11.1 channels. Representative immunoblots of transiently transfected HEK293 cells co-expressing WT with (a) PASD mutants, (b) C-linker/CNBHD mutants, or (c) pore mutants as heteromeric channels under control conditions (–), with culture at 27 °C (24 h) or culture in E4031 (E4, 24 h). Dashes (–) indicate the 140-kDa molecular weight marker. Yellow, orange and blue asterisks indicate correction at 27 °C, in E4031 or both, respectively, that were not correctable under those conditions as homomeric channels. H562P is also included, which was not completely dominant negative.

normally²⁸, underscoring the importance of this comprehensive large-scale analysis. Of the mutations studied electrophysiologically, nine show evidence for being class 3 (abnormal gating), including several shown for the first time in the CNBHD. Four were trafficking competent and generated minimal or no current, suggesting either a severe class 3 or a class 4 (altered permeation) mechanism. Several ‘mutations’ behave similar to WT, including most in the distal C-terminus, and it is unclear whether they are true LQT2 disease-causing mutations or benign variants.

Not surprisingly, we found that C-linker/CNBHD mutations behave similarly to PASD mutations. Since class 3 (abnormal gating) PASD mutations have been shown to disrupt ‘core’ interactions with the CNBHD⁶⁰, class 3 CNBHD mutations likely act similarly. Indeed, to our knowledge we identified the first class 3 CNBHD mutations as well as the first class 2 (trafficking-deficient) CNBHD mutations that can be corrected with culture in E4031. Figure 9a illustrates these similarities, where most mutations are destabilizing, resulting in misfolded channels with

Figure 9 | Model of Kv11.1 biogenesis and correction. (a) Model illustrating class 2 and/or class 3 loss-of-function phenotypes for EAGD and C-linker/CNBHD mutations. Mutations can either be destabilizing, resulting in misfolding and ERAD (top right, out of focus), or disrupt protein–protein interactions, resulting in quicker deactivation (bottom left, separated) or both (bottom right). (b) Summary of the trafficking phenotypes by domain for Kv11.1 homomeric channels and channels co-expressed with WT. Number of mutations analysed are in parentheses (see also Supplementary Tables 2–4). (c,d) Simplified five-step folding model illustrating the different correction phenotypes based on the data reported here and elsewhere (see Discussion). (c) The most destabilizing EAGD and C-linker/CNBHD mutations fail to make it to step 2 and undergo ERAD (red). These are uncorrectable at 27 °C or with E4. Less destabilizing mutations make it further along the folding pathway (step 2) and are amenable to 27 °C temperature correction but not E4 pharmacological correction (yellow). Mildly destabilizing mutations make it to step 3, where E4031, which acts posttranslationally, can facilitate cooperative interactions between subunits, allowing for correction¹³. (d) Pore mutations (orange) behave differently. Most are stable enough to make it to step 4, but result in severe dominant-negative effects causing both WT and mutant to undergo ERAD. These heteromeric channels fail to make it to step 5 (dashed outlines) required for ER exit, but can undergo improved folding and ER exit with pharmacological correction strategies.

reduced $I_{Kv11.1}$ density but nearly normal gating (for example, G53R, H70R and A78P)⁵⁰. Other mutations traffic normally but are located near gating microdomains, resulting in dysfunctional channels but with nearly normal $I_{Kv11.1}$ density (for example, R56Q, N33T, R835W, R791W)¹⁶. Finally, other mutations are both destabilizing (misfolded) and located in gating microdomains (dysfunctional) (for example, K28E, F29L, M124R, R784W and E788K)^{36,51}. This model might also help explain why G53R, H70R, A78P all exhibit faster deactivation in *Xenopus* oocytes but not in HEK293 cells^{50,51}. Misfolding mutations lying outside gating microdomains will still fail to form the ‘core’ interactions necessary for proper function, but are not marked for degradation in *Xenopus* oocytes, which are cultured at reduced temperature. However, the opposite is true for S706C, which was reported to have faster deactivation in *Xenopus* oocytes but not in this study using HEK293 cells³⁶. Clearly, differences between expression models need to be considered when evaluating LQT2 mutations, and perhaps studies in more native model systems would be useful^{61,62}.

Several lines of evidence suggest that correction of trafficking-deficient intracellular PASD and CNBHD mutations works at different steps along the folding pathway as illustrated in Fig. 9c. This model is supported by the following observations: (1) correction strategies typically work only for missense mutations with a diminished 155-kDa band, but not for mutations completely lacking a 155-kDa band; (2) the trafficking phenotype for several PASD mutations has been shown to correlate with domain stability^{28,63}; (3) all PASD and C-linker/CNBHD mutations that are E4031 correctable are also temperature correctable, suggesting that E4031 works further along the folding pathway where the pore is intact; and (4) E4031 acts posttranslationally¹³. Since the majority of mutations are correctable and therefore likely only slightly destabilizing, strategies that improve domain stability could help many LQT2–Kv11.1 channels evade ERAD⁶⁴.

Pore mutations are strikingly different from intracellular domain mutations. Two-thirds act in a completely dominant-negative manner when co-expressed with WT, in contrast to

intracellular mutations (Fig. 9d). Furthermore, heteromeric channels are much more amenable to pharmacological correction than homomeric channels (Fig. 9b). These results provide an explanation for the increased clinical severity of pore mutations, but also show more promise for pharmacological chaperones as a possible therapeutic approach⁶⁵.

While these studies have provided several new molecular insights into LQT2, many important questions remain. Since co-expression of WT can improve mutant Kv11.1 channel dysfunction⁶⁶, functional studies of co-expressed channels are needed. For example, Kv11.1 G657R appears to behave similar to a Shaker channel mutation that converts it from a K⁺ channel passing outward current to a K⁺ channel passing inward current at negative voltages⁶⁷. What loss-of-function mechanisms, if any, underlie the other Kv11.1 structural regions like the VSD⁶⁸ or the linker regions? Interestingly, as shown in Fig. 1, all reported SNPs lie in linker regions of the Kv11.1 protein lacking a highly ordered structure except for the CCD; thus, these areas may be more tolerant of amino-acid substitutions. Using the sequence-based prediction tools SIFT, SNP&Go and KvSNP, only 21–73% of mutations and 11–46% of SNPs were predicted to be pathogenic compared to 80–99% in structural domains (see Supplementary Tables 1 and 6). What are the structural bases for Kv11.1 misfolding? This is a largely unexplored area, but especially important since LQT2 is predominantly a misfolding disease. For example, do LQT2 missense mutations disrupt intra (local) and/or interdomain (global) interactions⁶⁹? Do TMD mutations insert less efficiently as predicted, which has been demonstrated for other channelopathies^{55,56}? Does L1049P disrupt the CCD as predicted? As a final example, it was surprising that both LQT2 mutations in the ER retention signal (R1005Q and R1007H) traffic normally. This suggests that these mutations do not disrupt binding of the distal C-terminus, which is thought to mask the RXR signal²⁰. These questions and many others remain unresolved, but this large-scale mutational analysis has shed new light on LQT2 disease mechanisms and may help the efforts towards developing rational approaches to predicting the pathogenic mechanism(s) of newly discovered Kv11.1 variants and correction strategies as clinically useful therapeutic options⁷⁰.

Methods

Mutation database and mutagenesis. LQT2-associated Kv11.1 missense mutations were identified predominantly from the Inherited Arrhythmias Database (www.fsm.it/cardmoc) and published genotyping from the various literature sources listed in Supplementary Table 1. All missense mutations were made using the QuikChange II XL kit from Agilent (Santa Clara, CA) using primers designed with their primer design program and obtained from Integrated DNA Technologies (Coralville, IA). A pcDNA3 WT HERG1a expression construct previously published was used as the template¹⁰. Restriction digest analysis was used to test the integrity of all constructs and all mutations were verified by sequencing at the UW-Biotechnology Center.

Bioinformatics. PASD structural models were created in Pymol using PDB: 1BYW. A Clinker/CNBHD structural model (Kv11.1 amino acids 672–864) was generated by Swiss-Model using the C-terminal structure from the homologous zELK KCNH (PDB: 3UKN) as a template. The quality of the model was evaluated using Molprobit and scored in the 56th percentile (100% being the best). After energy minimization using UCSF Chimera's minimization function, the model improved to the 91st percentile and was used for all subsequent modelling. Mutation pathogenicity was also evaluated for all mutations using the sequence-based programs SIFT, KvSNP, and SNPs&Go. Membrane insertion efficiency was predicted using the AG predictor. This tool predicts the apparent free energy difference for membrane insertion based on an experimentally determined biological hydrophobicity scale. Paircoil 2 was used to predict coiled-coil formation. Web servers and literature sources are listed in Supplementary Table 7.

Kv11.1 trafficking. HEK293 cells of similar confluence were transiently transfected with SuperFect (Qiagen) and grown at 37 °C for 24 h before study. Transfections were done with 3 µg of cDNA for homomeric expression or 1.5 µg mutant + 1.5 µg WT cDNA for co-expression. To test for correction of deficient Kv11.1 protein

trafficking, cells were grown for an additional 24 h at 37 °C for control, or at 27 °C, or in the presence of 10 µM E4031 (Alamone). Immature and mature Kv11.1 protein bands were detected by immunoblot analysis of whole-cell lysates. Briefly, lysates were mixed with an equal amount of Laemili sample buffer, separated by 7% SDS-PAGE, and transferred to a nitrocellulose paper. Blots were incubated with a rabbit antibody (1:10,000) directed to the distal C-terminus as previously described^{9,10}. Bands were detected with a goat anti-rabbit secondary antibody conjugated to HRP. Uncropped western blots are shown in Supplementary Fig. 2e.

Kv11.1 function. Stable cell lines were generated by transfecting HEK293 cells with mutant HERG pcDNA3 and selecting in G418 as previously described¹⁰. Single colonies of G418-resistant cells were then tested for Kv11.1 expression by immunoblot. Cell lines that gave a robust 155-kDa band on immunoblot were used for electrophysiological analysis. $I_{Kv11.1}$ was measured using the whole-cell patch clamp technique as previously described¹⁰. Voltage protocols are described in the Fig. 3 legend and data analysis was done using pCLAMP 8.0 (Axon Instruments) and Origin (6.0 Microcal).

Statistical analysis. All data are presented as mean ± s.e. One-way analysis of variance (ANOVA) was used for statistical analysis followed by the Tukey *post hoc* test. $P < 0.05$ was considered statistically significant.

References

- Curran, M. E. *et al.* A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. *Cell* **80**, 795–803 (1995).
- Tester, D. J. & Ackerman, M. J. Sudden infant death syndrome: How significant are the cardiac channelopathies? *Cardiovasc. Res.* **67**, 388–396 (2005).
- Brugada, R. *et al.* Sudden death associated with short-QT syndrome linked to mutations in HERG. *Circulation* **109**, 30–35 (2004).
- Crociani, O. *et al.* Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. *J. Biol. Chem.* **278**, 2947–2955 (2003).
- Johnson, J. N. *et al.* Identification of a possible pathogenic link between long QT syndrome and epilepsy. *Neurology* **27**, 224–231 (2009).
- Huffaker, S. J. *et al.* A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. *Nat. Med.* **15**, 509–518 (2009).
- Delisle, B. P., Anson, B. D., Rajamani, S. & January, C. T. Biology of cardiac arrhythmias: ion channel protein trafficking. *Circ. Res.* **94**, 1418–1428 (2004).
- Gong, Q., Zhang, L., Vincent, M. G., Horne, B. D. & Zhou, Z. Nonsense mutations in HERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long QT syndrome. *Circulation* **116**, 17–24 (2007).
- Zhou, Z., Gong, Q., Epstein, M. L. & January, C. T. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. *J. Biol. Chem.* **273**, 21061–21066 (1998).
- Anderson, C. L. *et al.* Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. *Circulation* **113**, 365–373 (2006).
- Gong, Q., Keeney, D. R., Molinari, M. & Zhou, Z. Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway. *J. Biol. Chem.* **280**, 19419–19425 (2005).
- Walker, V. E. *et al.* Hsp40 chaperones promote degradation of the HERG potassium channel. *J. Biol. Chem.* **285**, 3319–3329 (2010).
- Zhou, Z., Gong, Q. & January, C. T. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. *J. Biol. Chem.* **274**, 31123–31136 (1999).
- Lu, X. *et al.* RNA interference targeting E637K mutation rescues the hERG channel currents and restores its kinetic properties. *Heart Rhythm* **10**, 128–136 (2013).
- Matsa, E. *et al.* Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. *Eur. Heart J.* **35**, 1078–1087 (2013).
- Balijsapalli, S. Y., Anderson, C. L., Lin, E. C. & January, C. T. Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes. *J. Cardiovasc. Pharmacol.* **56**, 113–122 (2010).
- Doyle, D. A. *et al.* The structure of the potassium channel: molecular basis of K⁺ conduction and selectivity. *Science* **280**, 69–77 (1998).
- Morais-Cabral, J. H. *et al.* Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. *Cell* **95**, 649–655 (1998).
- Brelidze, T. I., Carlson, A. E., Sankaran, B. & Zagotta, W. N. Structure of the carboxy-terminal region of a KCNH channel. *Nature* **481**, 530–533 (2012).
- Kupersmidt, S. *et al.* Defective human ether-a-go-go-related gene trafficking linked to an endoplasmic reticulum retention signal in the C-terminus. *J. Biol. Chem.* **277**, 27442–27448 (2002).
- Jenke, M. *et al.* C-terminal domains implicated in the functional expression of potassium channels. *EMBO J.* **22**, 395–403 (2003).

22. Gong, Q., Anderson, C. L., January, C. T. & Zhou, Z. Pharmacological rescue of trafficking defective HERG channels formed by co-assembly of wild-type and long QT mutant N470D subunits. *Am. J. Physiol. Heart. Circ. Physiol.* **287**, H652–H658 (2004).
23. Vandenberg, J. I. *et al.* hERG K⁺ channels: structure, function, and clinical significance. *Physiol. Rev.* **92**, 1393–1478 (2012).
24. Kinoshita, K. *et al.* A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-a-go-go-related gene channel. *J. Cardiovasc. Electrophysiol.* **23**, 1246–1253 (2012).
25. Moss, A. J. *et al.* Increased risk of arrhythmic events in long QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. *Circulation* **105**, 794–799 (2002).
26. Shimizu, W. *et al.* Genotype-phenotype aspects of type 2 long QT syndrome. *J. Am. Coll. Cardiol.* **54**, 2052–2062 (2009).
27. Akhavan, A. *et al.* Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion channel cell-surface localization. *J. Cell Sci.* **118**, 2803–2812 (2005).
28. Harley, C. A., Jesus, C. S., Carvalho, R., Brito, R. M. & Morais-Cabral, J. H. Changes in channel trafficking and protein stability caused by LQT2 mutations in the PAS domain of the HERG channel. *PLoS One* **7**, e32654 (2012).
29. Li, Q. *et al.* NMR solution structure of the N-terminal domain of hERG and its interaction with the S4-S5 linker. *Biochem. Biophys. Res. Commun.* **403**, 126–132 (2010).
30. Muskett, F. W. *et al.* Mechanistic insight into human ether-a-go-go-related gene (hERG) K⁺ channel deactivation gating from the solution structure of the EAG domain. *J. Biol. Chem.* **286**, 6184–6191 (2011).
31. Gustina, A. S. & Trudeau, M. C. A recombinant N-terminal domain fully restores deactivation gating in N-truncated and long QT syndrome mutant hERG potassium channels. *Proc. Natl Acad. Sci. USA* **106**, 13082–13087 (2009).
32. Gustina, A. S. & Trudeau, M. C. hERG potassium channel gating is mediated by N- and C-terminal region interactions. *J. Gen. Physiol.* **137**, 315–325 (2011).
33. Gianulis, E. C., Liu, Q. & Trudeau, M. C. Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels. *J. Gen. Physiol.* **142**, 351–356 (2013).
34. de la Peña, P., Machin, A., Fernández-Trillo, J., Domínguez, P. & Barros, F. Mapping of interactions between amino and carboxy termini and the channel core in hERG K⁺ channels. *Biochem. J.* **451**, 463–474 (2013).
35. Haitin, Y., Carlson, A. E. & Zagotta, W. N. The structural mechanism of KCNH-channel regulation by the eag domain. *Nature* **501**, 444–448 (2013).
36. Al-Owais, M., Bracey, K. & Wray, D. Role of intracellular domains in the function of the herg potassium channel. *Eur. Biophys. J.* **38**, 569–576 (2009).
37. Krishnan, Y., Zheng, R., Walsh, C., Tang, Y. & McDonald, T. V. Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype. *Pacing Clin. Electrophysiol.* **35**, 3–16 (2012).
38. Paulussen, A. *et al.* A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency. *J. Biol. Chem.* **277**, 48610–48616 (2002).
39. Aidery, P. *et al.* Identification and functional characterization of the novel human ether-a-go-go related gene (hERG) R744P mutant associated with hereditary long QT syndrome type 2. *Biochem. Biophys. Res. Commun.* **418**, 830–835 (2012).
40. Huo, J. *et al.* The G604S-hERG mutation alters the biophysical properties and exerts a dominant-negative effect on expression of hERG channels in HEK293 cells. *Pflugers Arch.* **456**, 917–928 (2008).
41. Zhao, J. T. *et al.* Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant-negative trafficking defect and severe phenotype. *Cardiovasc. Electrophysiol.* **20**, 923–930 (2009).
42. Ficker, E., Obejero-Paz, C. A., Zhao, S. & Brown, A. M. The binding site for channel blockers that rescue misprocessed human Long QT Syndrome Type 2 ether-a-go-go-related gene (HERG) mutations. *J. Biol. Chem.* **277**, 4989–4998 (2002).
43. Fernandez, D., Ghanta, A., Kauffman, G. W. & Sanguinetti, M. C. Physicochemical features of the HERG channel drug-binding site. *J. Biol. Chem.* **279**, 10120–10127 (2004).
44. Rossenbacker, T. *et al.* Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. *Circulation* **111**, 961–968 (2005).
45. Delisle, B. P. *et al.* Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome. *Mol. Pharmacol.* **68**, 233–240 (2005).
46. Gong, Q., Jones, M. A. & Zhou, Z. Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. *J. Biol. Chem.* **281**, 4069–4074 (2006).
47. Ng, C. A. *et al.* The N-terminal tail of hERG contains an amphipathic α -helix that regulates deactivation. *PLoS One* **6**, e16191 (2011).
48. Wang, J., Myers, C. D. & Robertson, G. A. Dynamic control of deactivation gating by a soluble amino-terminal domain in HERG K channels. *J. Gen. Physiol.* **115**, 749–758 (2000).
49. Adaixo, R., Harley, C. A., Castro-Rodrigues, A. F. & Morais-Cabral, J. H. Structural properties of PAS domains from the KCNH potassium channels. *PLoS One* **8**, e59265 (2013).
50. Chen, J., Zhou, A., Splawski, I., Keating, M. T. & Sanguinetti, M. C. Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. *J. Biol. Chem.* **274**, 10113–10118 (1999).
51. Gianulis, E. C. & Trudeau, M. C. Rescue of aberrant gating by a genetically encoded PAS (Per-Arnt-Sim) domain in several long QT syndrome mutant human ether-a-go-go-related gene potassium channels. *J. Biol. Chem.* **286**, 22160–22169 (2011).
52. Shushi, L. *et al.* Clinical, genetic, and electrophysiologic characteristics of a new PaS-domain HERG mutation (M124R) causing Long QT syndrome. *Ann. Noninvasive Electrocardiol.* **10**, 334–341 (2005).
53. Brelidze, T. I., Carlson, A. E. & Zagotta, W. N. Absence of direct cyclic nucleotide modulation of mEAG1 and hERG1 channels revealed with fluorescence and electrophysiological methods. *J. Biol. Chem.* **284**, 27989–27997 (2009).
54. Farid, R., Day, T., Friesner, R. A. & Pearlstein, R. A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. *Bioorg. Med. Chem.* **14**, 3160–3173 (2006).
55. Choi, M. Y. *et al.* Destabilization of the transmembrane domain induces misfolding in a phenotypic mutant of cystic fibrosis transmembrane conductance regulator. *J. Biol. Chem.* **280**, 4968–4974 (2005).
56. Gallagher, M. J., Ding, L., Maheshwari, A. & MacDonald, R. L. The GABAA receptor α -1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation. *Proc. Natl Acad. Sci. USA* **104**, 12999–13004 (2007).
57. Rakoczy, E. P., Kiel, C., McKeone, R., Stricher, F. & Serrano, L. Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. *J. Mol. Biol.* **405**, 584–606 (2010).
58. Hessa, T. *et al.* Molecular code for transmembrane-helix recognition by the SEC61 translocon. *Nature* **450**, 1026–1030 (2007).
59. Zhang, L. *et al.* Contribution of hydrophobic and electrostatic interactions to the membrane integration of the Shaker K⁺ channel voltage sensor domain. *Proc. Natl Acad. Sci. USA* **104**, 8263–8268 (2007).
60. Gustina, A. S. & Trudeau, M. C. HERG potassium channel regulation by the N-terminal eag domain. *Cell Signal.* **24**, 1592–1598 (2012).
61. Lahti, A. L. *et al.* Model for long QT syndrome type 2 using human iPSCs demonstrates arrhythmogenic characteristics in cell culture. *Dis. Model Mech.* **5**, 220–230 (2012).
62. Itzhaki, I. *et al.* Modelling the long QT syndrome with induced pluripotent stem cells. *Nature* **471**, 225–230.
63. Ke, Y. *et al.* Trafficking defects in PAS domain mutant Kv11.1 channels: roles of reduced domain stability and altered domain-domain interactions. *Biochem. J.* **454**, 69–77 (2013).
64. Sampson, H. M. *et al.* Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. *Chem. Biol.* **18**, 231–242 (2011).
65. Peal, D. S. *et al.* Novel chemical suppressor of long QT syndrome identified by an in vivo functional screen. *Circulation* **123**, 23–30 (2011).
66. Balijepalli, S. Y. *et al.* Mechanism of loss of Kv11.1 K⁺ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating. *Circulation* **126**, 2809–2818 (2012).
67. Li, L., Liu, K., Hu, Y., Li, D. & Luan, S. Single mutations convert an outward K⁺ channel into an inward K⁺ channel. *Proc. Natl Acad. Sci. USA* **105**, 2871–2876 (2008).
68. McBride, C. M. *et al.* Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor. *J. Membr. Biol.* **246**, 355–364 (2013).
69. Bhaskara, R. M. & Srinivasan, N. Stability of domain structures in multi-domain proteins. *Sci. Rep.* **1**, 40 (2011).
70. Giudicessi, J. R. *et al.* Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome. *Circ. Cardiovasc. Genet.* **5**, 519–528 (2012).

Acknowledgements

We thank Dr Jennifer Poehls in the Dept. of Medicine and Dr Krishanu Saha in the Dept. of Biomedical Engineering at UW-Madison for helpful suggestions. We thank Dr Michael Ackerman (Mayo Clinic) for sharing pre-publication genotype information. This study was supported by the NIH R01 HL060723 (C.T.J.), an AHA Midwest Affiliate Predoctoral Fellowship (C.L.A.), a grant from the Saving tiny Hearts Society (B.P.D.) and a NIH training grant T32 HL07936 (Dr Jonathan C. Makielski).

Author contributions

C.L.A., C.E.K., R.R.C. and C.J.H. performed the experiments. C.L.A., B.P.D. and C.T.J. contributed to the study design and manuscript generation.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: Dr January is a co-founder of Cellular Dynamics International. Dr Delisle has a research contract with Gilead Scientific. The authors declare no other competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Anderson, C. L. *et al.* Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome. *Nat. Commun.* 5:5535 doi: 10.1038/ncomms6535 (2014).